Skip to main content

Catalyst Calendar

Scope

Thu, Oct 1, 2026

1 updates
NKTR
7:30 AM

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

In the news release, New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026, issued 01-Oct-2026 by Nektar Therapeutics over PR Newswire, formatting irregularities were introduced by PR Newswire

Presentation / Abstract • Phase 2oral presentation Thu, Oct 1, 2026nektar.com

Wed, Sep 30, 2026

1 updates
NKTR
10:30 AM

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai

Presentation / Abstract • Phase 2EADV late-breaking oral presentation Wed, Sep 30, 2026nektar.com

Mon, Sep 28, 2026

1 updates
NKTR
8:00 AM

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata Company to host conference call with investors and analysts on October 1, 2026 at 8:00 AM ET / 2:00 PM CET SAN FRANCISCO, Sept.

Results Call • Phase 2Results call Thu, Oct 1, 2026, 8:00 AM ETnektar.com

Fri, Sep 25, 2026

1 updates

Fri, Aug 28, 2026

1 updates

Tue, Aug 25, 2026

1 updates
NKTR
8:30 AM

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

REZOLVE-AD study met all primary and key secondary endpoints, including EASI -75, EASI -90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease

Trial Results • Phase 2Lancet publication of REZOLVE-AD Phase 2b results Tue, Aug 25, 2026nektar.com

Thu, Aug 13, 2026

1 updates
NKTR
4:15 PM

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities

Presentation / Abstract • Phase 2EADV oral presentation Thu, Oct 1, 2026, 10:25 AM CESTnektar.com

Tue, Jul 28, 2026

1 updates

Fri, Jul 24, 2026

1 updates

Tue, Jul 21, 2026

1 updates
NKTR
7:00 AM

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in EASI -100

Trial Start • Phase 3nektar.com